The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
Despite challenges related to the coronavirus pandemic, the Chinese precision oncology firm reported total quarterly revenues of RMB131.7 million ($20.2 million).
A UCLA-led team uncovered differences in DNA methylation patterns between patients with persistent and resolving methicillin-resistant Staphylococcus aureus infections.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
By bringing together epigenomic profiles for hundreds of tissue samples, researchers mapped regulatory modules relevant to a range of tissue and disease types.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
